ARUP LABORATORIES | aruplab.com

PATIENT REPORT

500 Chipeta Way, Salt Lake City, Utah 84108-1221 phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 55 years Male

Specimen Collected: 7/18/2025 1	0:44 MDT		
Aripipazole and Metabolite, Serum/Plasma	Received: 7/18/2	025 10:44 MDT	Report/Verified: 7/18/2025 10:46 MDT
Procedure	Result	Units	Reference Interval
Aripiprazole Serum/Plasma	418.5	ng/mL	
Dehydroaripiprazole, Serum/Plasma 121.7		ng/mL	
Total Aripiprazole and	540.2 H il	ng/mL	[150.0-350.0]
Metabolite S/P			

Test Information

il: Total Aripiprazole and Metabolite S/P

INTERPRETIVE INFORMATION: Aripipazole and Metabolite, Serum/Plasma

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to aripiprazole therapy may include headache, nausea, somnolence, and blurred vision.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

ARUP Accession: 25-199-900006 **Report Request ID**: 20596135

Printed: 7/18/2025 10:47 MDT

Page 1 of 1